Home/Pipeline/GJB2-GT

GJB2-GT

Early Presbycusis linked to GJB2

Pre-clinicalActive; CTA/IND preparation

Key Facts

Indication
Early Presbycusis linked to GJB2
Phase
Pre-clinical
Status
Active; CTA/IND preparation
Company

About Sensorion

Sensorion's mission is to find solutions for hearing disorders by building a portfolio of innovative therapies through its three strategic pillars: Restore, Treat, and Prevent. The company leverages a unique internal R&D platform to advance its pipeline, with key assets like OTOF-GT in Phase 1/2 and SENS-401 in Phase 2. Its clear strategy focuses on addressing a large, underserved market in inner ear diseases through both proprietary development and strategic partnerships.

View full company profile

About Sensorion

Sensorion's mission is to find solutions for hearing disorders by building a portfolio of innovative therapies through its three strategic pillars: Restore, Treat, and Prevent. The company leverages a unique internal R&D platform to advance its pipeline, with key assets like OTOF-GT in Phase 1/2 and SENS-401 in Phase 2. Its clear strategy focuses on addressing a large, underserved market in inner ear diseases through both proprietary development and strategic partnerships.

View full company profile

About Sensorion

Sensorion's mission is to find solutions for hearing disorders by building a portfolio of innovative therapies through its three strategic pillars: Restore, Treat, and Prevent. The company leverages a unique internal R&D platform to advance its pipeline, with key assets like OTOF-GT in Phase 1/2 and SENS-401 in Phase 2. Its clear strategy focuses on addressing a large, underserved market in inner ear diseases through both proprietary development and strategic partnerships.

View full company profile